PureTech (company)

PureTech Health plc develops new medicines. Its research engine generates therapeutics and candidates, which it advances toward regulatory approval. Some of its products have taken the whole path from founding to approval by the US Food and Drug Administration.

What PureTech Health offers

• Wholly owned pipeline — drug candidates developed in-house, such as LYT-200 for a blood cancer condition.
• Founded entities — companies created from its science, such as Gelesis and Akili.
• Collaborations — partnerships including a non-opioid programme with Imbrium.
• Investor resources — filings, financial reports, events and governance material.

Who it works with

Scientific collaborators, partners and shareholders. Its stated approach is to improve the effect of known treatments, make them oral or make them easier to tolerate.

Key facts

• Company type: public limited company
• Track record: its team oversaw research behind more than 15 regulatory approvals
• Recent news: fast track designation for LYT-200 after an end-of-phase 1 meeting with the FDA